| Name | Title | Contact Details |
|---|
BioAmber is a renewable chemistry company. We use agricultural crops and transform them into green chemicals that directly substitute chemicals derived from oil. BioAmber combines industrial biotechnology and chemical catalysis into a process that offers a better carbon footprint than petrochemicals. In addition to moving away from petroleum, our process consumes CO2, directly reducing greenhouse gas emissions and aiding in the fight against global warming. Bioamber is today the only producer of bio-succinic acid, a chemical building block used in a number of applications, such as plastics, polyurethane, solvents, personal care, plasticisers, etc.
NOCION is a biopharmaceutical company that is addressing vexing medical problems head on. We are developing `nocions`—a new kind of therapy that selectively affects actively firing nocioceptors—to provide targeted, robust and sustained relief for the treatment of serious conditions including cough, itch, pain and inflammation.
Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient`s unique cancer. The company`s clinical assays, FoundationOne for solid tumors and FoundationOne Heme for hematologic malignancies and sarcomas, provide a comprehensive genomic profile to identify the molecular alterations in a patient`s cancer and match them with relevant targeted therapies and clinical trials. Foundation Medicine`s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer.
BioExx Specialty Proteins Ltd. is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop next generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. Ambrx is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications. Specifically, ARX517, its proprietary antibody-drug conjugates (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. Ambrx spun out of The Scripps Research Institute in 2003 and has several other product candidates involving ADCs and other aspects of Ambrx`s protein engineering technology.